A PHASE Ib/ll, OPEN-LABEL, MULTICENTER, RANDOMIZED UMBRELLA STUDY EVALUATING THE EFFICACY AND SAFETY OF MUTIPLE IMMUNOTHERAPY -BASED TREATMENT COMBINATIONS IN PATIENTS WITH METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA (MORPHEUS-PANCREATIC CANCER)

The purpose of this study is to learn which treatment works best in patients with pancreatic cancer. The study explores multiple treatment combinations. A study drug called atezolizumab may be combined with other drugs such as cobimetinib, PEGPH20, and BL-8040. Patients may also be assigned to receive standard chemotherapy treatment. We Are Now Open To Enrollment For Wave 2.

Are you Eligible? (Inclusion Criteria)

• tients must have pancreatic ductal adenocarcinoma that continues to grow
• despite standard therapy.
• 2. Patients must be in good physical shape. This means that patients must be
• able to walk, care for themselves, and do light physical activities such as
• light housework or office work.
• 3. This study is for patients age 18 or older